知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

387 条记录 (耗时 0.016 秒)

    Process for preparing a vaccine against malaria
    61.
    发明授权
    Process for preparing a vaccine against malaria 失效
    制备抗疟疫苗的方法

    公开(公告)号：US5229110A

    公开(公告)日：1993-07-20

    申请号：US681711

    申请日：1991-04-08

    申请人： Philippe DuBois ,  Jean P. Dedet ,  Thierry G. Fandeur ,  Serge Pauillac ,  Christian P. Roussilhon ,  Luiz P. Pereira de Silva ,  Jurg Gysin

    发明人： Philippe DuBois ,  Jean P. Dedet ,  Thierry G. Fandeur ,  Serge Pauillac ,  Christian P. Roussilhon ,  Luiz P. Pereira de Silva ,  Jurg Gysin

    IPC分类号： A61K39/00 ,  C07K14/445 ,  C07K16/20

    CPC分类号： C07K16/205 ,  C07K14/445 ,  A61K39/00 ,  Y10S530/82 ,  Y10S530/822

    摘要： A process for preparing a vaccine against malaria comprising at least one polypeptide extracted from a schizont form of a strain of Plasmodium containing polypeptides antigenic to malaria. The polypeptides are recognized by immunoglobulin from a Saimiri Sciureus monkey resistant to the strain. The process includes the steps of:(a) treating a preparation of a strain of Plasmodium with a solution of a detergent which is able to separate the cellular structures from the parasite proteinic constituents;(b) recovering from the treated preparation, a polypeptide fraction having intact polypeptides of molecular weight ranging from about 70,000-85,000 or 90,000-120,000. The polypeptide fraction induces, in a first splenectomized Saimiri Sciureus monkey, a protective antibody against such strain, the polypeptides being recognized by immunoglobulin from a second Saimiri Sciureus monkey resistant to the strain. The immunoglobulin is capable, by an in vivo passive transfer to a third splenectomized Saimiri Sciureus monkey, sensitive to the strain, to protect the third monkey against the strain; and(c) adding a pharmaceutically acceptable vaccine.

    摘要翻译： 一种用于制备抗疟疾疫苗的方法，包括至少一种从疟原虫含疟原虫菌株的裂殖体形式提取的多肽。 所述多肽被抗菌株的Saimiri Sciureus猴免疫球蛋白识别。 该方法包括以下步骤：（a）用能够将细胞结构与寄生虫蛋白质组分分离的洗涤剂溶液处理疟原虫菌株的制剂; （b）从经处理的制剂中回收具有分子量范围为约70,000-85,000或90,000-120,000的完整多肽的多肽级分。 所述多肽部分在第一脾切除的Saimiri Sciureus猴中诱导针对该菌株的保护性抗体，所述多肽被免疫球蛋白识别，所述第二Saimiri Sciureus猴对该菌株有抗性。 免疫球蛋白能够通过体内被动转移到对该菌株敏感的第三脾切除的Saimiri Sciureus猴来保护第三只猴免受该菌株的侵害; 和（c）加入药学上可接受的疫苗。

    Protozoal antigen
    64.
    发明授权
    Protozoal antigen 失效
    原生动物抗原

    公开(公告)号：US4837016A

    公开(公告)日：1989-06-06

    申请号：US891055

    申请日：1986-07-31

    申请人： Anthony A. Holder ,  Robert R. Freeman

    发明人： Anthony A. Holder ,  Robert R. Freeman

    IPC分类号： A61K39/015 ,  A61K39/00 ,  A61K39/05 ,  A61K39/395 ,  C07K14/445 ,  C07K16/20 ,  C12P21/08 ,  C12R1/90

    CPC分类号： C07K16/205 ,  C07K14/445 ,  A61K39/00

    摘要： Protection inducing antigens or parasites of the genus Plasmodium are described. The antigens have an apparent molecular weight of 1.8 to 2.5.times.10.sup.5 and are associated with the membranes of the erythrocytic schizont forms of the parasite. The antigens may be incorporated into vaccines and used for the inducing of immunity into susceptible vetebrate hosts including humans. Methods for the preparation of the antigens are also described.

    摘要翻译： 描述了疟原虫属的保护诱导抗原或寄生虫。 抗原的表观分子量为1.8至2.5×10 5，并与寄生虫的红细胞裂殖体形式的膜相关。 抗原可以并入疫苗中，并用于诱导对包括人在内的易感性vetebrate宿主的免疫。 还描述了制备抗原的方法。

    METHODS OF IMMUNOTHERAPY
    67.
    发明公开
    METHODS OF IMMUNOTHERAPY 审中-公开

    公开(公告)号：US20240247051A1

    公开(公告)日：2024-07-25

    申请号：US18430151

    申请日：2024-02-01

    申请人： Yigal Adir

    发明人： Yigal Adir

    IPC分类号： C07K16/08 ,  A61K39/00 ,  C07K16/12 ,  C07K16/14 ,  C07K16/20

    CPC分类号： C07K16/08 ,  C07K16/12 ,  C07K16/14 ,  C07K16/20 ,  A61K2039/505 ,  C07K2317/10 ,  C07K2317/20

    摘要： The disclosure features a method which includes isolating an infectious agent from a human patient infected with the infectious agent, obtaining one or more immunoproteins, immunopolypeptides, and immunopeptides from serum from a non-domesticated wild animal by inoculating, in vivo, the non-domesticated wild animal with the isolated infectious agent or inoculating, in vitro, blood taken from the non-domesticated wild animal with the isolated infectious agent, comparing a protein, polypeptide, and peptide composition of serum obtained from blood from the non-domesticated wild animal inoculated in vivo or serum obtained from in vitro inoculated blood from the non-domesticated wild animal to that of a serum sample obtained from blood from the non-domesticated wild animal prior to inoculation or from non-inoculated blood, to identify the one or more immunoproteins, immunopolypeptides, and immunopeptides, and isolating and purifying the one or more immunoproteins, immunopolypeptides, and immunopeptides, and administering them to the infected human patient.

    Plasmodium with histamine releasing factor (HRF) deficiency for use as a vaccine
    69.
    发明授权
    Plasmodium with histamine releasing factor (HRF) deficiency for use as a vaccine 有权

    公开(公告)号：US11642404B2

    公开(公告)日：2023-05-09

    申请号：US17151516

    申请日：2021-01-18

    申请人： INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

    发明人： Salah Mecheri ,  Robert Menard ,  Claudia Demarta-Gatsi

    IPC分类号： A61K39/002 ,  A61K39/015 ,  A61P33/06 ,  A61K35/68 ,  C07K16/20 ,  G01N33/569 ,  A61K39/00

    CPC分类号： A61K39/015 ,  A61K35/68 ,  A61P33/06 ,  C07K16/205 ,  G01N33/56905 ,  A61K2039/5254 ,  G01N2333/445 ,  Y02A50/30

    摘要： A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 103 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 103 genetically a modified live Plasmodium.